Business Context and Reporting Period
This Form 8-K was filed by TherapeuticsMD, Inc. on March 28, 2014, reporting events that occurred between March 6 and March 27, 2014. The filing primarily addresses Regulation FD disclosures regarding a secondary public offering and related estate planning transactions involving a controlling stockholder.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on equity transactions and regulatory reporting obligations rather than operational financial performance.
Material Changes and Transactions
- Secondary Offering: On March 26, 2014, BF Investment Enterprises, Ltd. sold 421,268 shares of the Company's common stock in an underwritten secondary public offering. Jefferies LLC and Stifel, Nicolaus & Company served as representatives of the underwriters.
- Lock-Up Agreements: In connection with the offering, the Company, selling stockholders, and officers/directors entered into 90-day lock-up agreements restricting certain transactions in Company securities.
- Estate Planning Transactions: During March 2014, Brian Bernick, M.D. (a director, officer, and controlling holder of BF Investment), engaged in estate planning transactions. These included selling a non-controlling portion of membership interest in BF Management, LLC to a trust for his children and assigning limited partner interests in BF Investment to himself and his wife individually before selling portions to trusts.
- Form 4 Amendments: Due to subsequent valuation adjustments and prior calculation errors, Dr. Bernick filed a Form 4/A on March 27, 2014, to amend a previously filed Form 4 (dated March 10, 2014) regarding the estate planning transfers. A new Form 4 was also filed to report the secondary offering sale.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of general business risks. The document explicitly states that the information is furnished pursuant to Item 7.01 and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. It is not an admission as to the materiality of the information required solely by Regulation FD.
Investor Verification Checklist
- Verify the exact number of shares sold (421,268) and the underwriters involved (Jefferies LLC, Stifel, Nicolaus & Company) in the March 26, 2014 secondary offering.
- Confirm the terms and expiration date of the 90-day lock-up agreements entered into by officers and directors.
- Review the amended Form 4/A filed on March 27, 2014, to understand the corrected percentage of interests transferred by Dr. Bernick for estate planning purposes.
- Check subsequent filings to determine if the secondary offering proceeds were received by the Company or solely by the selling stockholder (BF Investment).